Discover how quality-driven drug development and AI accelerate safer medicines, reduce risk, and improve patient outcomes.

There has been much discussion recently about how artificial intelligence and machine learning (AI/ML) will revolutionize pharmaceutical research. Substantial progress has been made in the discovery ...

FDA's draft guidance shows gene therapy developers how to use prior knowledge and platform data to accelerate regulatory ...

AstraZeneca CEO Pascal Soriot said AI is helping the company develop medicines faster and make smarter decisions throughout ...

In this week’s edition of InnovationRx, we look at a new AI drug development deal, a pill for sleep apnea, Commure’s $7 billion valuation, and more.

The development of new medication by biotech and pharmaceutical companies, from target identification to marketing approval, is a time-consuming process with timelines extending to 12 years or more.

Developing a new medication can cost over $1 billion, depending on the drug’s complexity and expenses accrued via unsuccessful studies. Considering these costs, an optimized regulatory process is ...

Adequate representation of study populations in low- and middle-income countries in global anticancer drug development trials is critical to develop affordable and accessible cancer care with optimal ...